Jupiter Neurosciences Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company known for developing JOTROL, an enhanced orally administered resveratrol formulation, has introduced Nugevia, a direct-to-consumer longevity product line. The line targets mitochondrial support, mental clarity, and “beauty from within,” with cognitive health expected to account for about 60% of the company’s sales by volume, driven by the Nugevia MND supplement.
“Brain health is central to Jupiter’s DNA as a neuroscience company, and consumer awareness in this area is accelerating rapidly,” a Jupiter Neurosciences spokesperson said. “Our Nugevia MND formulation directly builds on our pharmaceutical expertise in neuroinflammation and CNS function, making it the most natural bridge between our clinical work and consumer wellness line.”
The global brain health supplement market is projected to reach approximately $23 billion by 2030, growing at a CAGR of around 13%. Jupiter Neurosciences positions Nugevia MND to meet this demand by addressing neuroinflammation, mitochondrial health, and cellular protection—pathways central to aging and cognition.
Jupiter’s expertise stems from its work on JOTROL, a resveratrol formulation designed for therapeutically relevant levels. Resveratrol had fallen out of favor due to poor bioavailability, but Jupiter’s delivery system achieves about nine times higher absorption and proven central nervous system penetration. JOTROL activates PARP-1, enhances cardiovascular health, and improves cognitive function. A phase one trial demonstrated safety and 8-10-fold higher blood plasma levels than naïve resveratrol. Phase two trials focus on Alzheimer’s, Parkinson’s, and other CNS disorders. JOTROL is patented in the U.S., Europe, China, Hong Kong, and Japan through 2036.
The Nugevia line includes MND, GLO, and PWR formulations, each featuring precision-engineered “intelligent stacking” of synergistic compounds for cellular resilience, blood-brain barrier delivery, and system-wide optimization. The company has enlisted brand ambassadors including former tennis star Annika Sörenstam, NBA legend Chris Webber, scientist Charbel Moussa, and biohacker Jean Fallacar to promote the products across diverse audiences.
“Jupiter Neurosciences is first and foremost a clinical-stage biotech company that has spent the past decade developing therapies for complex central nervous system disorders,” a company spokesperson said. “What makes our entry into the supplement space so unique is that we’re coming into it from the clinic, not the other way around. It’s a natural evolution of our dual-path strategy: advancing prescription therapies for patients while empowering everyday consumers with credible, evidence-based solutions for healthy aging.”
